Monoclonal antibodyFDA-approvedFirst-line
Rituximab
How it works
Binds to CD20 on B cells, marking them for destruction by the immune system.
Cancer types
Leukemia— CD20-positive
Efficacy
In clinical trials, around 60% of patients achieved a complete or partial response, with a median progression-free survival of approximately 12 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Rituximab Combination Therapy for Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| New Treatment Combination Tested in Younger Patients with Chronic Lymphocytic Leukemia | Leukemia | phase-2 | — | Source → |
| Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Leukemia | phase-2 | — | Source → |
| Testing Ibrutinib Alone or with Rituximab for Relapsed CLL | Leukemia | phase-2 | — | Source → |
| Testing Zanubrutinib and Rituximab for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Leukemia | phase-2 | — | Source → |
| Evaluating Treatments for Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Leukemia | phase-3 | — | Source → |
| Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | Leukemia | phase-2 | — | Source → |
| Comparing Treatments for Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Treating Older Adults with Untreated Chronic Lymphocytic Leukemia | Leukemia | phase-3 | — | Source → |
| Quality of Life in Hematology Patients Treated with Rituximab | Leukemia | observational | — | Source → |
| New Study Compares Pirtobrutinib to Standard Treatment for CLL/SLL | Leukemia | phase-3 | The 24-month PFS rate was 93.4% with pirtobrutinib and 70.7% with bendamustine plus rituximab. | Source → |
| Long-term results of Hairy cell leukemia treatment | Leukemia | phase-2 | A complete response was achieved in 133 of 137 evaluable participants (97%), with 102 (77%) having measurable residual disease negativity. | Source → |
| Rituximab with chemotherapy helps children with high-risk B-cell lymphoma | Leukemia | phase-3 | Three-year event-free survival was 97.7% (95% confidence interval, 84.9-99.7) and overall survival was 100%. | Source → |
| New Cancer Treatment Combination Shows Promise for Chronic Lymphocytic Leukemia | Leukemia | phase-2 | — | Source → |
| Advances in Hairy Cell Leukemia Treatment | Leukemia | review | — | Source → |
| Rituximab Cost-Effectiveness for CLL Treatment in Brazil | Leukemia | phase-3 | — | Source → |
| Venetoclax-Rituximab Treatment Shows Long-Term Benefits in CLL Patients | Leukemia | phase-3 | Survival benefits with VenR vs BR were sustained (median PFS: 53.6 vs 17.0 months, respectively, P < .0001; 5-year OS: 82.1% vs 62.2%, P < .0001). | Source → |
| Rituximab does not improve event-free survival in adult leukemia patients | Leukemia | phase-3 | — | Source → |
| Combining Medications for Chronic Lymphocytic Leukemia Treatment | Leukemia | phase-2 | The overall response rate was 88.37%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.